EVX Ventures

Carmine Therapeutics, established in 2019 and headquartered in Singapore, specializes in gene therapy. It produces extracellular vesicles from red blood cells as a non-viral, re-dosable gene delivery vehicle, addressing challenges posed by traditional viral-based therapies such as immunogenicity, limited transgene capacity, and manufacturing complexities. The company focuses on developing next-generation gene therapies for hematology, oncology, and immunology.

Nuevocor is a preclinical-stage biopharmaceutical company dedicated to developing gene therapy-based treatments aimed at restoring cardiac function in patients with cardiovascular diseases. The firm specifically targets genetic cardiomyopathies, which are characterized by abnormal mechanobiology. By focusing on modulating mechanical force transduction, Nuevocor aims to provide innovative solutions that enable healthcare professionals to effectively treat these conditions and improve heart health in affected individuals.